These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30909370)

  • 21. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apremilast in the treatment of psoriatic arthritis: a perspective review.
    Reed M; Crosbie D
    Ther Adv Musculoskelet Dis; 2017 Feb; 9(2):45-53. PubMed ID: 28255338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Spectrum of psoriatic conditions].
    Pouw JN; Leijten EFA; Tekstra J; Balak DMW; Radstake TRDJ
    Ned Tijdschr Geneeskd; 2019 Jul; 163():. PubMed ID: 31361418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T; Puig L
    Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.
    Raychaudhuri SP; Wilken R; Sukhov AC; Raychaudhuri SK; Maverakis E
    J Autoimmun; 2017 Jan; 76():21-37. PubMed ID: 27836567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
    Wittmann M; Helliwell PS
    Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecule therapy for managing moderate to severe psoriatic arthritis.
    Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
    Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical potential of apremilast in the treatment of psoriatic arthritis.
    Cauli A; Porru G; Piga M; Vacca A; Dessole G; Mathieu A
    Immunotargets Ther; 2014; 3():91-6. PubMed ID: 27471702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence.
    Sideris E; Corbett M; Palmer S; Woolacott N; Bojke L
    Pharmacoeconomics; 2016 Nov; 34(11):1101-1110. PubMed ID: 27272887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
    J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.
    Dal Bello G; Gisondi P; Idolazzi L; Girolomoni G
    Rheumatol Ther; 2020 Jun; 7(2):271-285. PubMed ID: 32306243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.